# Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Source: https://onco.cc/trials/nct06942234/  
OnCo record `nct06942234` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JSKN016, Capecitabine, Eribulin and Pembrolizumab in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, now recruiting.

## Summary

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer is a phase 1/2 interventional study registered as NCT06942234 by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, with 180 participants planned, started 2025-06-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: JSKN016, Capecitabine, Paclitaxel (albumin bound), Eribulin and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06942234
- Phase: 1/2
- Setting: The Multicenter, Open-label, Single-arm, Multi-cohort Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of JSKN016 in Combination Therapy in Chinese Participants With Inoperable Locally Advanced or Metastatic HER2-negative Breast Cancer
- Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06942234: https://clinicaltrials.gov/study/NCT06942234

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Eribulin](https://onco.cc/drugs/eribulin/), [JSKN016](https://onco.cc/drugs/jskn016/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Alphamab Oncology](https://onco.cc/companies/alphamab/)

---
JSON: https://onco.cc/api/v1/entities/nct06942234.json